Botanix Pharmaceuticals Ltd (ASX: BOT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Botanix Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$236.41 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.97 billion
Earnings per share
-0.047
Dividend per share
N/A
Year To Date Return
-14.81%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Botanix Pharmaceuticals Ltd (ASX: BOT)
Latest News
Share Gainers
These ASX cannabis shares have smoked the market in 2019
Share Gainers
Why cannabinoid company Botanix rocketed 25% higher today
Share Gainers
Why these ASX cannabis shares surged higher today
Share Market News
ASX small-cap AusCann Group ramps up cannabis research
Share Gainers
These 3 small cap ASX shares are surging higher today
Share Gainers
These 3 small cap ASX shares are climbing higher today
⏸️ Investing
Up in smoke: What happened to the ASX pot stocks?
⏸️ Investing
Why these 4 ASX shares are jumping higher today
⏸️ Investing
Why these 4 ASX shares are climbing higher today
⏸️ Investing
These 3 small cap shares are storming higher today
⏸️ Investing
Are these the next ASX biotech stars?
⏸️ Investing
Australian medicinal cannabis industry Q1 update
BOT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.
BOT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 05 Feb 2026 | $0.12 | $0.00 | 0.00% | 7,955,055 | $0.11 | $0.12 | $0.11 |
| 04 Feb 2026 | $0.12 | $0.01 | 9.52% | 7,496,141 | $0.11 | $0.12 | $0.10 |
| 03 Feb 2026 | $0.11 | $0.00 | 0.00% | 2,260,580 | $0.11 | $0.11 | $0.10 |
| 02 Feb 2026 | $0.10 | $-0.01 | -9.09% | 9,332,657 | $0.11 | $0.11 | $0.10 |
| 30 Jan 2026 | $0.11 | $0.00 | 0.00% | 10,300,243 | $0.11 | $0.12 | $0.10 |
| 29 Jan 2026 | $0.11 | $-0.01 | -8.33% | 4,178,632 | $0.12 | $0.12 | $0.11 |
| 28 Jan 2026 | $0.12 | $0.00 | 0.00% | 9,139,988 | $0.12 | $0.12 | $0.11 |
| 27 Jan 2026 | $0.12 | $-0.01 | -8.00% | 8,518,400 | $0.13 | $0.13 | $0.12 |
| 23 Jan 2026 | $0.13 | $-0.01 | -7.69% | 1,484,673 | $0.13 | $0.13 | $0.13 |
| 22 Jan 2026 | $0.13 | $0.00 | 0.00% | 6,726,713 | $0.13 | $0.14 | $0.13 |
| 21 Jan 2026 | $0.13 | $-0.01 | -7.41% | 3,233,761 | $0.14 | $0.14 | $0.13 |
| 20 Jan 2026 | $0.14 | $0.01 | 7.69% | 799,600 | $0.14 | $0.14 | $0.13 |
| 19 Jan 2026 | $0.13 | $-0.01 | -7.41% | 3,817,588 | $0.14 | $0.14 | $0.13 |
| 16 Jan 2026 | $0.14 | $-0.01 | -7.14% | 2,375,756 | $0.14 | $0.14 | $0.13 |
| 15 Jan 2026 | $0.14 | $0.01 | 7.41% | 2,227,337 | $0.14 | $0.14 | $0.13 |
| 14 Jan 2026 | $0.14 | $0.00 | 0.00% | 2,113,920 | $0.14 | $0.14 | $0.13 |
| 13 Jan 2026 | $0.14 | $-0.01 | -7.14% | 10,145,881 | $0.14 | $0.15 | $0.13 |
| 12 Jan 2026 | $0.14 | $0.00 | 0.00% | 4,986,734 | $0.15 | $0.15 | $0.14 |
| 09 Jan 2026 | $0.14 | $0.01 | 7.41% | 7,365,883 | $0.14 | $0.15 | $0.14 |
| 08 Jan 2026 | $0.14 | $0.00 | 0.00% | 5,270,992 | $0.14 | $0.15 | $0.14 |
| 07 Jan 2026 | $0.14 | $0.01 | 7.69% | 9,586,876 | $0.13 | $0.14 | $0.13 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 08 Oct 2025 | Vince Ippolito | Transfer | 8,000,000 | $1,120,000 |
Off-market transfer.
|
| 08 Oct 2025 | Vince Ippolito | Transfer | 8,000,000 | $1,120,000 |
Off-market transfer.
|
| 20 Mar 2025 | Daniel Sharp | Issued | 3,111,145 | $1,353,348 |
Exercise of options.
|
| 20 Mar 2025 | Daniel Sharp | Exercise | 4,000,000 | $1,740,000 |
Exercise of options.
|
| 27 Feb 2025 | Stewart Washer | Issued | 3,990,099 | $1,815,495 |
Exercise of options.
|
| 27 Feb 2025 | Stewart Washer | Exercise | 5,000,000 | $2,275,000 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Stewart James Washer | Non-Executive Director | Feb 2019 |
Dr Washer has board experience in medical biotech and device companies. He has founded several ASX listed and private companies. He chaired Hatchtech Pty Ltd that was sold in 2015 for AUD$279m and was a director of iCeutica that was sold to US private equity investors in 2010. He has been a Senator with Murdoch University and a director of AusBiotech Ltd. He is also a member of the risk committee.
|
| Dr H. William Bosch | Non-Executive Director | Jul 2023 |
Dr Bosch has 30 years of experience and industry leadership in pharmaceutical R&D. He served as CSO of iCeutica where he was the principal architect of SoluMatrix drug delivery technology, used in four FDA approved prescription drug products. Earlier in his career, he led the use of nanotechnology in drug development. He served as a co-founder of NanoSystems LLC in 1995 and co-inventor of NanoCrystal Technology. He is also a member of the risk committee.
|
| Mr Vince Ippolito | PresidentExecutive ChairmanExecutive Director | May 2019 |
Mr Ippolito has 40 years of experience in the pharmaceuticals industry, including over 30 years of experience in dermatology. He most recently served as President and Chief Operating Officer of Dermavant Sciences, a specialty biopharmaceutical company that is commercialising products which treat inflammatory skin diseases and medical dermatologic conditions. Prior to his role at Dermavant Sciences, he served as the Chief Commercial Officer and Executive Vice President of Anacor Pharmaceuticals, a dermatology-based biopharmaceutical company.
|
| Mr Daniel Sharp | Non-Executive Director | Mar 2022 |
Mr Sharp has 30 years of experience in capital markets globally, advising the boards of technology and healthcare-based organisations. He has experience in sourcing and servicing institutional and private wealth investors globally. He was a Corporate Finance Executive Director of Canaccord Genuity for 8 years and previously spearheaded the Corporate Finance departments at Shaw and Partners and Lodge Partners. He is chair of the risk committee.
|
| Dr Patricia Walker | Non-Executive Director | Aug 2025 |
Dr Walker previously served as Chief Medical Advisor for Botanix Pharmaceuticals through her consulting company, Walker Consulting, Dr Walker put her experience to work teaching the next generation of dermatologists as a member of the Clinical Faculty, Department of Dermatology, University of California, Irvine She is also in securing corporate financing, product licenses, joint development efforts and initial public offerings.
|
| Mr Andrew Bickley | Company Secretary | Oct 2025 |
-
|
| Dr Howie McKibbon | Chief Executive Officer | Aug 2023 |
-
|
| Howie McKibbon | Chief Executive Officer |
-
|
|
| Mr Graeme Morissey | Chief Financial Officer Australia |
-
|
|
| Mr Chris Lesovitz | Chief Financial Officer United States of America |
-
|
|
| Andrew Bickley | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| J P Morgan Nominees Australia Pty Limited | 106,965,835 | 5.45% |
| HSBC Custody Nominees (Australia) Limited | 106,807,887 | 5.45% |
| National Nominees Limited | 88,160,864 | 4.50% |
| Shenasaby Investments Pty Ltd <Shenasaby A/C> | 54,586,791 | 2.78% |
| Caperi Pty Ltd cCaperi A/C> | 52,573,784 | 2.68% |
| BNP Paribas Nominees Pty Ltd <IB AU Norns Retailclient> | 44,724,873 | 2.28% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 39,903,663 | 2.03% |
| Citicorp Nominees Pty Limited | 37,167,682 | 1.90% |
| Netwealth Investments Limited <Wrap Services A/C> | 28,540,016 | 1.46% |
| Zenith Pacific Limited | 23,952,649 | 1.22% |
| Warbont Nominees Pty Ltd cUnpaid Entrepot A/C> | 20,215,485 | 1.03% |
| Dr Henry William Bosch | 18,836,702 | 0.96% |
| Vince Ippolito | 15,001,644 | 0.76% |
| Yarraandoo Pty Ltd <Yarraandoo Super Fund A/C> | 14,500,000 | 0.74% |
| BNP Paribas Norns Pty Ltd | 14,361,839 | 0.73% |
| Rollo Corp Property Holdings Pty Ltd <RolIo Corp Property A/C> | 13,750,000 | 0.70% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 12,629,631 | 0.64% |
| Dr Howard McKibbon | 11,313,391 | 0.58% |
| UBS Nominees Pty Ltd | 9,523,810 | 0.49% |
| Mr Lisheng Wang | 9,346,586 | 0.48% |
